Pairing of single-cell RNA analysis and T cell antigen receptor profiling indicates breakdown of T cell tolerance checkpoints in atherosclerosis
- PMID: 37621765
- PMCID: PMC10448629
- DOI: 10.1038/s44161-023-00218-w
Pairing of single-cell RNA analysis and T cell antigen receptor profiling indicates breakdown of T cell tolerance checkpoints in atherosclerosis
Abstract
Atherosclerotic plaques form in the inner layer of arteries triggering heart attacks and strokes. Although T cells have been detected in atherosclerosis, tolerance dysfunction as a disease driver remains unexplored. Here we examine tolerance checkpoints in atherosclerotic plaques, artery tertiary lymphoid organs and lymph nodes in mice burdened by advanced atherosclerosis, via single-cell RNA sequencing paired with T cell antigen receptor sequencing. Complex patterns of deteriorating peripheral T cell tolerance were observed being most pronounced in plaques followed by artery tertiary lymphoid organs, lymph nodes and blood. Affected checkpoints included clonal expansion of CD4+, CD8+ and regulatory T cells; aberrant tolerance-regulating transcripts of clonally expanded T cells; T cell exhaustion; Treg-TH17 T cell conversion; and dysfunctional antigen presentation. Moreover, single-cell RNA-sequencing profiles of human plaques revealed that the CD8+ T cell tolerance dysfunction observed in mouse plaques was shared in human coronary and carotid artery plaques. Thus, our data support the concept of atherosclerosis as a bona fide T cell autoimmune disease targeting the arterial wall.
Conflict of interest statement
Competing interests S.K.M., A.J.R.H. and C.Y. declare competing interests. C.Y., S.K.M. and A.J.R.H. are owners of Easemedcontrol R&D & Co KG, Munich, Germany; C.Z., A.J.R.H. and C.Y. are inventors on a pending patent application related to the diagnostics and therapeutic usages of TCRs/B cell receptors to treat atherosclerosis. The remaining authors declare no competing interests.
Figures
Comment in
-
Understanding autoimmunity in atherosclerosis paves the way for novel therapies.Nat Cardiovasc Res. 2023 Mar;2(3):227-229. doi: 10.1038/s44161-023-00230-0. Nat Cardiovasc Res. 2023. PMID: 39196001 No abstract available.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials